Illumina, Merck partner on HRD test

By staff writers

September 8, 2021 -- Illumina and Merck have agreed to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD).

Illumina will leverage its TruSight oncology (TSO) 500 content to develop a new HRD CDx test for the European Union and the U.K. to aid in the identification of ovarian cancer patients with positive HRD status who are eligible for treatment with Lynparza, an (ADP-ribose) polymerase inhibitor.

Lynparza was developed and commercialized by Merck, which is known as MSD outside the U.S. and Canada, and AstraZeneca.

Additionally, Illumina will develop and commercialize a research use only (RUO) HRD assay that will be add-on content for the TSO 500 RUO panel. Illumina plans to launch this product globally, excluding the U.S. and Japan.

Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...
Illumina donates $60M in NGS tools to build genomic network
Illumina is donating $60 million in next-generation sequencing (NGS) platforms, reagents, and support to create a comprehensive pathogen genomic...
Illumina partners with German university on genome sequencing
Illumina is joining forces with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen in Germany on whole-genome...
Illumina sees mixed results for Q4, fiscal year
Illumina increased its revenue for its fourth quarter, but revenues declined for the full year. The company's net income also increased for the most recent...
Illumina claims another win in BGI patent dispute, this time in U.K.
Illumina claimed another success in its patent infringement litigation against BGI over its sequencing-by-synthesis technology, with a favorable judgment...

Copyright © 2021

Last Updated ls 9/8/2021 1:37:25 PM